{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:43:50Z","timestamp":1795139030315,"version":"4.10.3"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clineuro.2025.109222","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:46:49Z","timestamp":1761810409000},"page":"109222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Systematic review of novel target therapies and clinical trials in chordoma"],"prefix":"10.1016","volume":"259","author":[{"given":"Maryam","family":"Zeinali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid Qoorchi Moheb","family":"Seraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-7937","authenticated-orcid":false,"given":"Michael","family":"Karsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clineuro.2025.109222_bib1","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/cncr.28032","article-title":"Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population","volume":"119","author":"Smoll","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clineuro.2025.109222_bib2","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","article-title":"Chordoma: current concepts, management, and future directions","volume":"13","author":"Walcott","year":"2012","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.clineuro.2025.109222_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100771","article-title":"Chordoma: current status, problems, and future directions","volume":"45","author":"Wedekind","year":"2021","journal-title":"Curr. Probl. Cancer"},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib4","doi-asserted-by":"crossref","DOI":"10.3171\/2024.2.FOCUS249","article-title":"Stereotactic radiosurgery in the management of skull base chordomas: a comprehensive systematic review and meta-analysis","volume":"56","author":"Maroufi","year":"2024","journal-title":"Neurosurg. Focus"},{"issue":"4","key":"10.1016\/j.clineuro.2025.109222_bib5","first-page":"369","article-title":"Controversies in neuro-oncology: focal proton versus photon radiation therapy for adult brain tumors","volume":"11","author":"Eekers","year":"2024","journal-title":"Neurooncol Pract."},{"key":"10.1016\/j.clineuro.2025.109222_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110418","article-title":"Hypofractionated proton and carbon ion beam radiotherapy for sacrococcygeal chordoma (ISAC): an open label, randomized, stratified, phase II trial","volume":"198","author":"Seidensaal","year":"2024","journal-title":"Radio. Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","article-title":"Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy","volume":"15","author":"Joshi","year":"2024","journal-title":"Discov. Oncol."},{"issue":"3","key":"10.1016\/j.clineuro.2025.109222_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.clineuro.2025.109222_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fonc.2019.00030","article-title":"Molecular targeted therapy in the treatment of chordoma: a systematic review","volume":"9","author":"Meng","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.clineuro.2025.109222_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1535-7163.MCT-17-0324","article-title":"Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury","volume":"17","author":"Magnaghi","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92018-0","article-title":"Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma","volume":"11","author":"Lohberger","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10143-014-0579-x","article-title":"Immunohistochemical expression of receptor tyrosine kinase PDGFR-\u03b1, c-Met, and EGFR in skull base chordoma","volume":"38","author":"Akhavan-Sigari","year":"2015","journal-title":"Neurosurg. Rev."},{"key":"10.1016\/j.clineuro.2025.109222_bib13","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.2147\/CMAR.S252185","article-title":"miR-100-5p inhibits malignant behavior of chordoma cells by targeting IGF1R","author":"Zhang","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib14","article-title":"Clinical-proteomic classification and precision treatment strategy of chordoma","volume":"5","author":"Yin","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"45","key":"10.1016\/j.clineuro.2025.109222_bib15","doi-asserted-by":"crossref","first-page":"73984","DOI":"10.18632\/oncotarget.12172","article-title":"Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF\/GETO)","volume":"7","author":"Lebellec","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11060-019-03221-z","article-title":"Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma","volume":"144","author":"Morimoto","year":"2019","journal-title":"J. Neurooncol."},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib17","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdv300","article-title":"Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF\/GETO)","volume":"26","author":"Bompas","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70026-w","article-title":"Synergistic drug combinations and machine learning for drug repurposing in chordoma","volume":"10","author":"Anderson","year":"2020","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl3674","article-title":"Personalized chordoma organoids for drug discovery studies","volume":"8","author":"Al Shihabi","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-017-01026-0","article-title":"The driver landscape of sporadic chordoma","volume":"8","author":"Tarpey","year":"2017","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3171\/2017.1.JNS162610","article-title":"A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab","volume":"128","author":"Fujii","year":"2017","journal-title":"J. Neurosurg."},{"issue":"18","key":"10.1016\/j.clineuro.2025.109222_bib22","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-14-3270","article-title":"Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4\/6 cell-cycle pathway","volume":"75","author":"von Witzleben","year":"2015","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.clineuro.2025.109222_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/2767-9764.CRC-21-0020","article-title":"Combinatorial natural killer cell\u2013based immunotherapy approaches selectively target chordoma cancer stem cells","volume":"1","author":"Hoke","year":"2021","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.clineuro.2025.109222_bib24","unstructured":"Kornelson K. Understanding brachyury Genetics and Developing Strategies to Target brachyury in chordoma. 2023."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234103","article-title":"Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer","volume":"15","author":"Frame","year":"2020","journal-title":"Plos One"},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14101028","article-title":"Impact of CDK inhibitors on TBXT expression in chordoma cell lines including the first stable cell line of a high-grade chordoma","volume":"14","author":"Bette","year":"2024","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.clineuro.2025.109222_bib27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.chembiol.2020.10.001","article-title":"Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors","volume":"28","author":"Richters","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting transcription cycles in cancer","volume":"22","author":"Vervoort","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41467-021-21026-5","article-title":"Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival","volume":"12","author":"Bai","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib30","article-title":"The mutational landscape of spinal chordomas and their sensitive detection using circulating tumor DNA","volume":"3","author":"Mattox","year":"2021","journal-title":"Neurooncol. Adv."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/gcc.22362","article-title":"Genomic aberrations frequently alter chromatin regulatory genes in chordoma","volume":"55","author":"Wang","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib32","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/humu.24427","article-title":"Rare germline variants in PALB2 and BRCA2 in familial and sporadic chordoma","volume":"43","author":"Xia","year":"2022","journal-title":"Hum. Mutat."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101283","article-title":"Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1","volume":"9","author":"Choy","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib34","doi-asserted-by":"crossref","DOI":"10.3171\/2024.2.FOCUS2417","article-title":"Unraveling molecular advancements in chordoma tumorigenesis and treatment response: a review of scientific discoveries and clinical implications","volume":"56","author":"Jin","year":"2024","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.clineuro.2025.109222_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1048482","article-title":"Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clineuro.2025.109222_bib36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.wneu.2023.02.062","article-title":"De novo versus secondary dedifferentiated chordomas: a population-based analysis and integrated individual participant data meta-analysis","volume":"173","author":"Vuong","year":"2023","journal-title":"World Neurosurg."},{"issue":"2","key":"10.1016\/j.clineuro.2025.109222_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/gcc.22511","article-title":"High sensitivity of FISH analysis in detecting homozygous SMARCB1 deletions in poorly differentiated chordoma: a clinicopathologic and molecular study of nine cases","volume":"57","author":"Owosho","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clineuro.2025.109222_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.808021","article-title":"Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms","volume":"12","author":"Walker","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib40","first-page":"1","article-title":"Inhibiting cancer cell hallmark features through nuclear export inhibition","volume":"1","author":"Sun","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"issue":"24","key":"10.1016\/j.clineuro.2025.109222_bib41","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1038\/s41388-020-1324-2","article-title":"Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target","volume":"39","author":"Yang","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1078-0432.CCR-22-1865","article-title":"Gene expression profiling identifies two chordoma subtypes associated with distinct molecular mechanisms and clinical outcomes","volume":"29","author":"Bai","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.clineuro.2025.109222_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8020248","article-title":"The importance of the hedgehog signaling pathway in tumorigenesis of spinal and cranial chordoma","volume":"8","author":"Akhavan-Sigari","year":"2019","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.clineuro.2025.109222_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.semdp.2020.05.005","article-title":"SWI\/SNF complex-deficient soft tissue neoplasms: an update","volume":"38","author":"Schaefer","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"issue":"2","key":"10.1016\/j.clineuro.2025.109222_bib45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.celrep.2017.09.057","article-title":"Brachyury-YAP regulatory axis drives stemness and growth in cancer","volume":"21","author":"Shah","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib46","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41467-019-09891-7","article-title":"BRD9 defines a SWI\/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.clineuro.2025.109222_bib47","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajpath.2022.12.012","article-title":"SMARCB1 loss in poorly differentiated chordomas drives tumor progression","volume":"193","author":"Walhart","year":"2023","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.clineuro.2025.109222_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1009193","article-title":"Emerging target discovery and drug repurposing opportunities in chordoma","volume":"12","author":"Freed","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib49","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41467-019-09633-9","article-title":"Defective homologous recombination DNA repair as therapeutic target in advanced chordoma","volume":"10","author":"Gr\u00f6schel","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00432-024-05706-5","article-title":"Germline findings in cancer predisposing genes from a small cohort of chordoma patients","volume":"150","author":"Raygada","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cpr.12204","article-title":"Epigenetic deregulations in chordoma","volume":"48","author":"Yu","year":"2015","journal-title":"Cell Prolif."},{"issue":"20","key":"10.1016\/j.clineuro.2025.109222_bib52","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/0008-5472.CAN-20-1387","article-title":"Inhibition of histone H3K27 Demethylases Inactivates Brachyury (TBXT) and promotes chordoma cell Death","volume":"80","author":"Cottone","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15252\/embr.201744201","article-title":"BRACHYURY directs histone acetylation to target loci during mesoderm development","volume":"19","author":"Beisaw","year":"2018","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-023-01610-0","article-title":"DNA methylation, combined with RNA sequencing, provide novel insight into molecular classification of chordomas and their microenvironment","volume":"11","author":"Baluszek","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"issue":"4","key":"10.1016\/j.clineuro.2025.109222_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC Class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.clineuro.2025.109222_bib56","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib57","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1158\/1078-0432.CCR-18-3133","article-title":"Immunologic correlates of the abscopal effect in a SMARCB1\/INI1-negative poorly differentiated chordoma after EZH2 inhibition and radiotherapy","volume":"25","author":"Gounder","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.clineuro.2025.109222_bib58","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3390\/cancers14061486","article-title":"Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft","volume":"14","author":"Passeri","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.clineuro.2025.109222_bib59","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3892\/ol.2024.14395","article-title":"MicroRNA\u20111224 inhibits cell proliferation by downregulating CBX3 expression in chordoma","volume":"27","author":"Xia","year":"2024","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41420-023-01332-1","article-title":"The malignancy of chordomas is enhanced via a circTLK1\/miR-16-5p\/Smad3 positive feedback axis","volume":"9","author":"Lou","year":"2023","journal-title":"Cell Death Discov."},{"issue":"6","key":"10.1016\/j.clineuro.2025.109222_bib61","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41419-018-0738-z","article-title":"miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.clineuro.2025.109222_bib62","doi-asserted-by":"crossref","first-page":"9987","DOI":"10.2147\/OTT.S222380","article-title":"Upregulation of miR-149-3p suppresses spinal chordoma malignancy by targeting Smad3","volume":"12","author":"Yao","year":"2019","journal-title":"Onco Targ. Ther."},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib63","first-page":"5533","article-title":"MicroRNA profiling and bioinformatics analyses reveal the potential roles of microRNAs in chordoma","volume":"14","author":"Chen","year":"2017","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib64","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1186\/s12885-023-11238-x","article-title":"Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma","volume":"23","author":"Huo","year":"2023","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.clineuro.2025.109222_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119423","article-title":"Targeting IGF2BP3 in Cancer","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11060-013-1274-4","article-title":"Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma","volume":"116","author":"Zhou","year":"2014","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11033-023-09017-9","article-title":"Dysregulation of noncoding RNA in chordoma; implications in identifying potential targets for novel therapeutic approaches","volume":"51","author":"Ghosh","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"12","key":"10.1016\/j.clineuro.2025.109222_bib68","first-page":"6313","article-title":"The critical roles of lnc-GLYATL2-2\/PD-L1 axis in immune microenvironment and the clinical value of intracranial chordomas","volume":"13","author":"Wang","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.clineuro.2025.109222_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112366","article-title":"Targeted delivery of cancer drug paclitaxel to chordomas tumor cells via an RNA nanoparticle harboring an EGFR aptamer","volume":"212","author":"Xiao","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.clineuro.2025.109222_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1376622","article-title":"Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence","volume":"14","author":"Lopez","year":"2024","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.clineuro.2025.109222_bib71","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.18632\/oncotarget.3576","article-title":"Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma","volume":"6","author":"Feng","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib72","first-page":"3274","article-title":"Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis","volume":"8","author":"Zou","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"6","key":"10.1016\/j.clineuro.2025.109222_bib73","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.spinee.2015.11.059","article-title":"CSPG4 as a prognostic biomarker in chordoma","volume":"16","author":"Schoenfeld","year":"2016","journal-title":"Spine J."},{"key":"10.1016\/j.clineuro.2025.109222_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1257254","article-title":"The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clineuro.2025.109222_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113315","article-title":"Tumor-derived IL-6 promotes chordoma invasion by stimulating tumor-associated macrophages M2 polarization and TNF\u03b1 secretion","volume":"143","author":"Chen","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.clineuro.2025.109222_bib76","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3390\/pharmaceutics15041274","article-title":"High-throughput\/high content imaging screen identifies novel small molecule inhibitors and immunoproteasomes as therapeutic targets for chordoma","volume":"15","author":"Ajay","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1429","article-title":"Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma","volume":"13","author":"Huo","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib78","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-019-02349-1","article-title":"Clinicopathological implications of TIM3(+) tumor-infiltrating lymphocytes and the miR-455-5p\/Galectin-9 axis in skull base chordoma patients","volume":"68","author":"Zhou","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.clineuro.2025.109222_bib79","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1007\/s12094-020-02387-7","article-title":"Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma","volume":"22","author":"He","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.clineuro.2025.109222_bib80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00262-017-2080-1","article-title":"Clinicopathologic implications of CD8+\/Foxp3+ ratio and miR-574-3p\/PD-L1 axis in spinal chordoma patients","volume":"67","author":"Zou","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clineuro.2025.109222_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659662","article-title":"B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma","volume":"11","author":"Long","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib82","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41416-024-02635-5","article-title":"Single-cell sequencing reveals VEGFR as a potential target for CAR-T cell therapy in chordoma","volume":"130","author":"Wu","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib83","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.clineuro.2025.109222_bib84","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.clineuro.2025.109222_bib85","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.1158\/1078-0432.CCR-17-1087","article-title":"Phase I study of a poxviral TRICOM-based vaccine directed against the transcription factor brachyury","volume":"23","author":"Heery","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109222_bib86","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1634\/theoncologist.2019-0932","article-title":"Phase I trial of a modified vaccinia ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors","volume":"25","author":"Collins","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib87","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1002\/onco.13720","article-title":"Randomized, double-blind, placebo-controlled Phase II study of yeast-brachyury vaccine (GI-6301) in combination with standard-of-care radiotherapy in locally advanced, unresectable chordoma","volume":"26","author":"DeMaria","year":"2021","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.clineuro.2025.109222_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003238","article-title":"Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer","volume":"9","author":"DeMaria","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.clineuro.2025.109222_bib89","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2326-6066.CIR-15-0119","article-title":"Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury","volume":"3","author":"Heery","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"7738","key":"10.1016\/j.clineuro.2025.109222_bib90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"6382","key":"10.1016\/j.clineuro.2025.109222_bib91","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clineuro.2025.109222_bib92","article-title":"Immune microenvironment and immunotherapy for chordoma","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"issue":"7662","key":"10.1016\/j.clineuro.2025.109222_bib93","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.clineuro.2025.109222_bib94","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.clineuro.2025.109222_bib95","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov."},{"issue":"12","key":"10.1016\/j.clineuro.2025.109222_bib96","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1158\/1078-0432.CCR-15-2218","article-title":"Phase I dose-escalation study of linsitinib (OSI-906) and erlotinib in patients with advanced solid tumors","volume":"22","author":"Macaulay","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clineuro.2025.109222_bib97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2017.03.037","article-title":"Advanced chordoma treated by first-line molecular targeted therapies: outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF\/GETO) and the association des neuro-oncologues d\u2032Expression Fran\u00e7aise (ANOCEF)","volume":"79","author":"Lebellec","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.clineuro.2025.109222_bib98","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00701-017-3163-7","article-title":"Clival chordoma: a single-centre outcome analysis","volume":"159","author":"J\u00e4gersberg","year":"2017","journal-title":"Acta Neurochir. (Wien. )"},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib99","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.clineuro.2025.109222_bib100","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1002\/cncr.31685","article-title":"Imatinib and everolimus in patients with progressing advanced chordoma: a phase 2 clinical study","volume":"124","author":"Stacchiotti","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clineuro.2025.109222_bib101","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.ijrobp.2018.07.2013","article-title":"A phase 1 study of nilotinib plus radiation in high-risk chordoma","volume":"102","author":"Cote","year":"2018","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109222_bib102","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.clineuro.2025.109222_bib103","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S1470-2045(20)30466-6","article-title":"Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study","volume":"21","author":"Liu","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.clineuro.2025.109222_bib104","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.clineuro.2025.109222_bib105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/CJI.0000000000000431","article-title":"Immune checkpoint inhibitors have clinical activity in patients with recurrent chordoma","volume":"45","author":"Bishop","year":"2022","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.clineuro.2025.109222_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101569","article-title":"Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study","volume":"8","author":"Le Cesne","year":"2023","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.clineuro.2025.109222_bib107","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.clineuro.2025.109222_bib108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1158\/1078-0432.CCR-23-2317","article-title":"Pilot study of high-dose pemetrexed in patients with progressive chordoma","volume":"30","author":"Kesari","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725005050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725005050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T21:56:35Z","timestamp":1763675795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846725005050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":108,"alternative-id":["S0303846725005050"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109222","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of novel target therapies and clinical trials in chordoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109222"}}